Oarsman Capital, Inc. Galectin Therapeutics Inc Transaction History
Oarsman Capital, Inc.
- $562 Million
- Q4 2024
A detailed history of Oarsman Capital, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Oarsman Capital, Inc. holds 9,698 shares of GALT stock, worth $12,510. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,698
Previous 9,698
-0.0%
Holding current value
$12,510
Previous $26,000
57.69%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding GALT
# of Institutions
114Shares Held
10.3MCall Options Held
3.78MPut Options Held
5.27M-
Vanguard Group Inc Valley Forge, PA2.19MShares$2.83 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.02 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA871KShares$1.12 Million0.0% of portfolio
-
Geneos Wealth Management Inc.427KShares$551,3910.01% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $76.7M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...